AFP、CEA、CA199、CA-125联合检测对肝癌、肝硬化诊断的临床价值

目的 探讨肿瘤标志物甲胎蛋白(AFP)、癌胚抗原(CEA)、糖类抗原199(CA-199)、糖类抗原125(CA125)联合检测对肝癌、肝硬化诊断的临床价值.方法 抽取37例肝癌、40例肝硬化、40例健康对照者血清,利用罗氏e601全自动电化学发光仪进行AFP、CEA、CA-199、CA125的联合检测.结果 37例肝癌患者血清AFP、CEA、CA-199、CA125水平显著高于健康对照组(t分别为1.35,3.51,1.88,2.74,P<0.05),阳性率分别为59.4%,37.8%,45.9%,42.3%,联合检测AFP、CEA、CA-199、CA125诊断肝癌阳性率为78.3%;肝硬化患者的阳性率分别为32.5%,30.0%,42.5%,72.5%,肝硬化患者血清CA125水平明显高于肝癌患者及健康对照组,阳性率分别为72.5%,42.3%,2.5%.结论 AFP、CEA、CA199、CA125联合检测可提高肝癌的阳性诊断率;CA125对诊断肝硬化较肝癌敏感性高,对鉴别诊断有一定意义.